Trial Profile
A Randomized, Open-Label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 27 Feb 2012 Actual end date Dec 2010 added as reported by ClinicalTrials.gov (NCT00805675).
- 27 Feb 2012 Actual end date Dec 2010 added as reported by ClinicalTrials.gov (NCT00805675).
- 27 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT00805675).